XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

BACKGROUND: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer. METHODS: Patients previously untreated for metastatic disease were randomized in: group A (irinotecan, capecitabine, bevacizumab, eve...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Pectasides, Dimitrios, Papaxoinis, George, Kalogeras, Konstantine T, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Makatsoris, Thomas, Samantas, Epaminondas, Varthalitis, Ioannis, Papakostas, Pavlos, Nikitas, Nikitas, Papandreou, Christos N, Pentheroudakis, George, Timotheadou, Eleni, Koutras, Angelos, Sgouros, Joseph, Bafaloukos, Dimitrios, Klouvas, George, Economopoulos, Theofanis, Syrigos, Konstantinos N, Fountzilas, George
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2012
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3466131/
https://ncbi.nlm.nih.gov/pubmed/22748098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-271
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi